Fine-Tuning the Treatment Algorithm in Adv Head & Neck Cancer - priME Oncology
Expert Perspectives
Expert Perspectives

Fine-Tuning the Treatment Algorithm in Adv Head & Neck Cancer

Not a member of My prIME? Join now for instant access.

Get insights from the head and neck squamous cell cancer (HNSCC) experts on treatment options for advanced HNSCC, including combination therapies and immunotherapies. Watch the videos, download the slides, and impact your practice.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

0.25 AMA PRA Category 1 Credit™

Release Date

Release Date

Oct 13, 2017

Expiration Date

Oct 13, 2018

  • Ana Castro, MDCentro Hospitalar do Porto
    Porto, Portugal
  • Lisa Licitra, MD, PhDFondazione IRCCS - Istituto Nazionale dei Tumori
    Milan, Italy
  • Amanda Psyrri, MD, PhDNational and Kapodistrian University of Athens
    Attikon University Hospital
    Athens, Greece
  • Jan Vermorken, MD, PhDAntwerp University Hospital
    Antwerp, Belgium
  • The evolving treatment algorithm for advanced HNSCC
  • Scenario #1—Locally advanced HNSCC: Options for cisplatin-ineligible patients
  • Scenario #2—Recurrent/metastatic HNSCC: Front-line therapy and beyond
  • Scenario #3—Progression on immunotherapy in recurrent/metastatic HNSCC
  • prIME Points™

This educational activity is specifically designed for medical oncologists, radiation oncologists, head and neck surgeons, and other healthcare professionals involved in the treatment of patients with head and neck cancer.

After successful completion of this educational activity, participants should be able to:

  • Explain multidisciplinary approaches for managing HPV+ and HPV- locally advanced HNSCC
  • Select an optimal treatment sequence for patients with recurrent/metastatic HNSCC
  • Evaluate therapeutic options for advanced HNSCC after progression on immunotherapy and identify ongoing research strategies in advanced HNSCC, including combinations of conventional therapies and immunotherapies

This educational activity is supported by a grant from Merck KGaA, Darmstadt, Germany.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Fine-Tuning the Treatment Algorithm in Adv Head & Neck Cancer - prIME Oncology

prIME Oncology designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Castro has disclosed that she received consulting fees from Astellas, Bristol-Myers Squibb, Merck Serono, and MSD. She has also performed contracted research for or received research support from Amgen, AstraZeneca, Merck Serono, and Pfizer. She has received fees for non-CME services directly from Astellas, Bristol-Myers Squibb, Janssen, Merck Serono, MSD, and Pfizer. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Licitra has disclosed receipt of grants or research/support either to her or to her institution in her role as consultant/advisory from AstraZeneca, Bayer (also travel support), Bristol-Myers Squibb, Boehringer Ingelheim, Eisai, Merck-Serono (also travel support), MSD, Novartis, and Roche. She also disclosed receipt of honoraria or consultation fees either to her or her institution in her role as consultant/advisory from AstraZeneca (also research funds), Bristol-Myers Squibb, Debiopharm (also travel support), EISAI (also research funds), Merck-Serono (also research funds and travel support), MSD (also research funds), and SOBI (also travel support). She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Psyrri has disclosed that she received consulting fees from AstraZeneca and MSD. She also performed contracted research for or received research support from AstraZeneca. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Vermorken has disclosed that he received consulting fees from Amgen, AstraZeneca, BCI Biotech, MSD, Innate Pharma, Merck KGaA, and Synthon. He also received fees for non-CME services directly from Merck KGaA and Sanofi. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Bojana Pajk, MD, MSc (medical director content reviewer/planner) – no relevant financial relationships
  • Sanneke Koekkoek, RN (scientific content reviewer/planner) – no relevant financial relationships
  • Christi Gray (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.